Dofetilide antiarrhythmic prescription drug recalled for manufacturing deviations
Accord Healthcare is recalling 113,571 bottles of dofetilide capsules distributed in the US, Puerto Rico, and Canada due to Current Good Manufacturing Practice (CGMP) deviations found during FDA inspection. No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II drug recall, indicating potential for adverse health consequences, but no illnesses, injuries, or reported adverse effects are documented. The hazard is manufacturing non-compliance (CGMP deviations) without a specified safety defect.
Plain-English summary
Accord Healthcare, Inc. is recalling dofetilide 250 mcg capsules sold in the United States, including Puerto Rico and Canada. The recall affects approximately 113,571 bottles. Dofetilide is an oral prescription antiarrhythmic medication.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations discovered during an FDA inspection. CGMP deviations indicate non-compliance with FDA manufacturing standards for quality and process control.
Multiple batch numbers are affected, with expiration dates ranging from February 2023 through May 2025. Patients currently taking dofetilide should not stop the medication without consulting their healthcare provider. Contact a healthcare professional or pharmacist to determine if your medication is affected and for guidance on appropriate next steps.
The recalled product
- Product
- DOFETILIDE (DOFETILIDE)
- Brand
- DOFETILIDE
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Antiarrhythmic
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: P2101481 Exp. Date 2/28/2023
- P2101985
- P2101958
- P2102019
- Exp. Date 3/31/2023
- P2102580
- P2102597
- Exp. Date 4/30/2023
- P2104708
- P2104712
- Exp. Date 6/30/2023
- P2107154
- P2107187
- Exp. Date 10/31/2023
- P2107874
- Exp. Date 11/30/2023
- P2200772
- P2200796
- P2200830
- Exp. Date 12/31/2023
UPCs (1)
- 316729491129
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · DOFETILIDE
- ModerateDofetilide Capsules Recalled Due to Out-of-Specification Content Uniformity
FDA (Drugs) · 2023-08-16
- ModerateFDA Recalls Dofetilide Antiarrhythmic Drug for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- ModeratePrescription Drug Dofetilide Recalled Due to Manufacturing Compliance Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27